163 related articles for article (PubMed ID: 38079423)
21. [Phenotyping of angiotensin-converting enzyme in the prostate in patients with prostate cancer and benign prostatic hyperplasia].
Mamedov VN; Danilov SM; Samokhodskaya LM; Okhobotov DA; Kamalov DM; Melnikov N; Karpov VK; Kadrev AV; Kamalov AA
Urologiia; 2020 Nov; (5):20-27. PubMed ID: 33185341
[TBL] [Abstract][Full Text] [Related]
22. Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population.
Qi J; Tian L; Chen Z; Wang L; Tao S; Gu X; Na R; Jiao Y; Kang J; Zheng S; Xu J; Sun J
Prostate; 2013 Aug; 73(11):1182-90. PubMed ID: 23620269
[TBL] [Abstract][Full Text] [Related]
23. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
Fu Q; Yao DH; Jiang YQ
Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
[TBL] [Abstract][Full Text] [Related]
25. Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer.
Aydin M; Bozkurt A; Cikman A; Gulhan B; Karabakan M; Gokce A; Alper M; Kara M
Int Braz J Urol; 2017; 43(1):36-46. PubMed ID: 28124524
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients.
Cimino S; Favilla V; Russo GI; Galvano F; Li Volti G; Barbagallo I; Giofrè SV; D'Orazio N; DI Rosa A; Madonia M; Morgia G
Anticancer Res; 2014 Sep; 34(9):5051-6. PubMed ID: 25202090
[TBL] [Abstract][Full Text] [Related]
27. [Value of nomogram based on the ultrasonographic features of prostatic calcification and varicocele and serological indicators in differential diagnosis of prostate cancer].
Xie YD; Sun G; Xu CL
Zhonghua Nan Ke Xue; 2022 Jul; 28(7):596-602. PubMed ID: 37556216
[TBL] [Abstract][Full Text] [Related]
28. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer.
Montie JE; Pienta KJ
Urology; 1994 Jun; 43(6):892-9. PubMed ID: 7515207
[TBL] [Abstract][Full Text] [Related]
29. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
30. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
[TBL] [Abstract][Full Text] [Related]
32. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
33. The value of ESWAN in diagnosis and differential diagnosis of prostate cancer: Preliminary study.
Xin JY; Gao SS; Liu JG; Sun CF; Han Y; Sun XH; Wang XZ; Wang B
Magn Reson Imaging; 2017 Dec; 44():26-31. PubMed ID: 28782677
[TBL] [Abstract][Full Text] [Related]
34. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
[TBL] [Abstract][Full Text] [Related]
35. Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia.
Liu Y; Zhao X; Sun X; Li Y; Wang Z; Jiang J; Han H; Shen W; Corrigan CJ; Sun Y
Prostate; 2015 Dec; 75(16):1844-56. PubMed ID: 26356122
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas.
Yue L; Wang T; Ge Y; Ge M; Zhang C; Hou Q; Wang W; Tian H; Ren B; Du B; Zhang W
Prostate; 2019 Feb; 79(3):312-319. PubMed ID: 30450670
[TBL] [Abstract][Full Text] [Related]
37. Oxidative damage in patients with benign prostatic hyperplasia and prostate cancer co-exposed to phthalates and to trace elements.
Chang WH; Lee CC; Yen YH; Chen HL
Environ Int; 2018 Dec; 121(Pt 2):1179-1184. PubMed ID: 30808488
[TBL] [Abstract][Full Text] [Related]
38. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
39. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
40. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
Dai X; Fang X; Ma Y; Xianyu J
Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
